Join the Migraine Prevention group to help and get support from people like you.
Migraine Prevention News (Page 3)
Triptans, Ergots, Antiemetics Most Effective Meds for Migraine
WEDNESDAY, Nov. 29, 2023 – Triptans, ergots, and antiemetics are the most effective classes of medications for migraine, according to a study published online Nov. 29 in Neurology. Chia-Chun Chiang,...
Ubrogepant Beneficial for Treating Migraine During the Prodrome
WEDNESDAY, Nov. 22, 2023 – Ubrogepant is beneficial for the treatment of migraine when taken during the prodrome, according to a study published online Nov. 15 in The Lancet. David W. Dodick, M.D.,...
Adverse Childhood Experiences Linked to Headache in Adulthood
FRIDAY, Oct. 27, 2023 – Adverse childhood experiences (ACEs) are associated with primary headache in adulthood, according to a review published online Oct. 25 in Neurology. Claudia Sikorski, Ph.D.,...
Childhood Trauma Raises Odds for Adult Headaches
THURSDAY, Oct. 26, 2023 – Children who live through trauma may be prone to having headaches as an adult. New research found an association between headache disorders and traumatic events in...
FDA Approves Eprontia (topiramate) Oral Solution for Epilepsy and Preventive Treatment of Migraine
WOBURN, MA, November 8, 2021 – Azurity Pharmaceuticals, Inc. a private specialty pharmaceutical company focused on developing innovative products to meet the unique needs of patients with underserved ...
FDA Approves Biohaven's Nurtec ODT (rimegepant) for Preventative Treatment of Migraine
Nurtec ODT 75 mg is the first oral CGRP antagonist approved to prevent migraine Nurtec ODT 75 mg is now the only migraine medication approved to both treat acute migraine attacks and help prevent...
Teva Announces FDA Approval of Ajovy (fremanezumab-vfrm) Injection Autoinjector
PARSIPPANY, N.J.--(BUSINESS WIRE) January 28, 2020 – Teva Pharmaceuticals USA, Inc. an affiliate ofTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Food and Drug...
FDA Approves Aimovig (erenumab-aooe) as a Preventive Treatment for Migraine
May 17, 2018 – The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly...
FDA Approves Topamax for Migraine Prevention in Adolescents
March 28, 2014 – Today, the U.S. Food and Drug Administration approved Topamax (topiramate) for prevention (prophylaxis) of migraine headaches in adolescents ages 12 to 17. This is the first FDA...
FDA Medwatch Alert: Valproate Anti-Seizure Products: Drug Safety Communication - Contraindicated for Pregnant Women for Prevention of Migraine Headaches
Including valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP, and Depakote ER), valproic acid (Depakene and Stavzor), and their generics ISSUE: FDA is advising health care...
Further information
Related condition support groups
Related drug support groups
lisinopril, clonazepam, metoprolol, bupropion, amlodipine, amitriptyline, propranolol, Topamax, lamotrigine, view more... pregabalin, Depakote, atenolol, topiramate, baclofen, clonidine, nortriptyline, Botox, Emgality, Aimovig, erenumab, Ajovy, nifedipine, verapamil, Qulipta